Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, Morris B, Cesaroni M, Proost N, Beijersbergen RL, van Lohuizen M, Gargiulo G.

J Exp Med. 2018 Dec 3;215(12):3115-3135. doi: 10.1084/jem.20180801. Epub 2018 Nov 28.

2.

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Šuštić T, van Wageningen S, Bosdriesz E, Reid RJD, Dittmar J, Lieftink C, Beijersbergen RL, Wessels LFA, Rothstein R, Bernards R.

Genome Med. 2018 Nov 27;10(1):90. doi: 10.1186/s13073-018-0600-z.

3.

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R.

J Hepatol. 2018 Nov;69(5):1057-1065. doi: 10.1016/j.jhep.2018.07.004. Epub 2018 Jul 18.

PMID:
30030148
4.

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK.

Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082.

5.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R.

Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.

PMID:
29808006
6.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 Aug;37(33):4611-4625. doi: 10.1038/s41388-018-0300-6. Epub 2018 May 15.

7.

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R.

Cell Res. 2018 Jun;28(6):690-692. doi: 10.1038/s41422-018-0020-z. Epub 2018 Mar 5. No abstract available.

PMID:
29507396
8.

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R.

Mol Cancer Ther. 2018 Apr;17(4):849-857. doi: 10.1158/1535-7163.MCT-17-0868. Epub 2018 Feb 13.

PMID:
29440296
9.

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity.

Dohmen AJC, Qiao X, Duursma A, Wijdeven RH, Lieftink C, Hageman F, Morris B, Halonen P, Vens C, van den Brekel MWM, Ovaa H, Neefjes J, Zuur CL.

Oncotarget. 2017 May 19;8(43):73925-73937. doi: 10.18632/oncotarget.18034. eCollection 2017 Sep 26.

10.

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, Lieftink C, Morris B, Jochems F, Willemsen L, Beijersbergen RL, Bernards R.

Cell Rep. 2017 Oct 17;21(3):773-783. doi: 10.1016/j.celrep.2017.09.085.

11.

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.

Eur Urol. 2017 Jun;71(6):858-862. doi: 10.1016/j.eururo.2017.01.021. Epub 2017 Jan 17.

PMID:
28108151
12.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R.

Oncotarget. 2016 Jun 21;7(25):37407-37419. doi: 10.18632/oncotarget.9822.

13.

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

Miles DC, de Vries NA, Gisler S, Lieftink C, Akhtar W, Gogola E, Pawlitzky I, Hulsman D, Tanger E, Koppens M, Beijersbergen RL, van Lohuizen M.

Stem Cells. 2017 Jan;35(1):147-157. doi: 10.1002/stem.2453. Epub 2016 Jul 6.

14.

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS.

Oncotarget. 2016 Jul 12;7(28):42859-42872. doi: 10.18632/oncotarget.10230.

15.

Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formation.

van Heesbeen RGHP, Raaijmakers JA, Tanenbaum ME, Halim VA, Lelieveld D, Lieftink C, Heck AJR, Egan DA, Medema RH.

Chromosoma. 2017 Aug;126(4):473-486. doi: 10.1007/s00412-016-0607-4. Epub 2016 Jun 29.

16.

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.

de Lint K, Poell JB, Soueidan H, Jastrzebski K, Vidal Rodriguez J, Lieftink C, Wessels LF, Beijersbergen RL.

Mol Cancer Ther. 2016 Jul;15(7):1545-56. doi: 10.1158/1535-7163.MCT-15-0865. Epub 2016 May 11.

17.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R.

Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059.

18.

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM.

Clin Cancer Res. 2016 Aug 1;22(15):3884-93. doi: 10.1158/1078-0432.CCR-15-1874. Epub 2016 Mar 2.

19.

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

Heynen GJ, Nevedomskaya E, Palit S, Jagalur Basheer N, Lieftink C, Schlicker A, Zwart W, Bernards R, Bajpe PK.

Mol Cancer Res. 2016 May;14(5):411-22. doi: 10.1158/1541-7786.MCR-15-0291-T. Epub 2016 Jan 19.

20.

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R.

Cell Rep. 2015 Sep 29;12(12):1978-85. doi: 10.1016/j.celrep.2015.08.037. Epub 2015 Sep 10.

21.

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation.

Kostova EB, Beuger BM, Klei TR, Halonen P, Lieftink C, Beijersbergen R, van den Berg TK, van Bruggen R.

Biosci Rep. 2015 Apr 16;35(2). pii: e00187. doi: 10.1042/BSR20150019.

22.

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

Possik PA, Müller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, Krijgsman O, Song JY, Smit MA, Gerritsen B, Lieftink C, Kemper K, Michaut M, Beijersbergen RL, Wessels L, Schumacher TN, Peeper DS.

Cell Rep. 2014 Nov 20;9(4):1375-86. doi: 10.1016/j.celrep.2014.10.024. Epub 2014 Nov 6.

23.

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A.

Cell Rep. 2014 Sep 11;8(5):1475-83. doi: 10.1016/j.celrep.2014.07.033. Epub 2014 Sep 4.

24.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R.

Cell Rep. 2014 Apr 10;7(1):86-93. doi: 10.1016/j.celrep.2014.02.045. Epub 2014 Mar 27.

25.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

26.

IntAct--open source resource for molecular interaction data.

Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, Derow C, Dimmer E, Feuermann M, Friedrichsen A, Huntley R, Kohler C, Khadake J, Leroy C, Liban A, Lieftink C, Montecchi-Palazzi L, Orchard S, Risse J, Robbe K, Roechert B, Thorneycroft D, Zhang Y, Apweiler R, Hermjakob H.

Nucleic Acids Res. 2007 Jan;35(Database issue):D561-5. Epub 2006 Dec 1.

Supplemental Content

Loading ...
Support Center